Peer-Reviewed Publication
Lancet Neurol2026;25(10):939-951.October 1, 2026Journal Article
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.
Tammie L S Benzinger1, Petrice M Cogswell2, Arvin Arani2, Aisling M Chaney3, Kent Hutson4, Matthew F Glasser3, Jonathan Graff-Radford5, Jon McConathy6, Cyrus A Raji3, Charlotte Teunissen7, Prashanthi Vemuri8, Greg Zaharchuk9, Clifford R Jack2
1Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: benzingert@wustl.edu.
2Department of Radiology, Mayo Clinic, Rochester, MN, USA.
3Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
4Radiology Partners, Austin, TX, USA.
5Department of Neurology, Mayo Clinic, Rochester, MN, USA.
6Department of Radiology, The University of Alabama at Birmingham, Birmingham, AL, USA.
7Neurochemistry Laboratory, Department of Laboratory Medicine, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
8Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
9Department of Radiology, Stanford University, Stanford, CA, USA.
Abstract
Disease-modifying therapies and biomarker-based diagnostic frameworks will fundamentally altered the clinical diagnosis and management of Alzheimer's disease. Diagnosis is increasingly anchored in the biological evidence of pathology rather than clinical presentation alone, with implications for treatment eligibility, prognosis, and monitoring. In clinical practice, patients with memory complaints…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans